Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05100654 · ClinicalTrials.gov registry record · Early Phase 1

Collaborative Urological Prosthetics Investigation Directive Research Group

A Early Phase 1 study of Erectile Dysfunction and Penile Prosthesis Infection, sponsored by University of Chicago.

Active
Registry status
Early Phase 1
Development phase
800
Enrollment target
1
Study location

NCT05100654: Active Early Phase 1 study of Erectile Dysfunction and Penile Prosthesis Infection, sponsored by University of Chicago.

NCT05100654 is a Early Phase 1 study of Erectile Dysfunction and Penile Prosthesis Infection that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 800 participants, above the 207-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (286% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05100654, a Early Phase 1 study of Erectile Dysfunction and Penile Prosthesis Infection, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
800 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if an additional 6 days of oral antibiotics decreases the risk of penile prosthesis infection after implantation.

Primary Outcome

From day of surgery through 1 year we are hoping to show that additional 6 days of oral antibiotics do not decrease the risk of penile prosthesis infection requiring surgical intervention for device removal.

Interventions

  • DRUG Ciprofloxacin
  • DRUG Doxycycline
  • DRUG Augmentin
  • DRUG Bactrim

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2022-04-22
Est. Completion 2028-01-01
Phase Early Phase 1
University of Chicago

796 total trials

What the registry record for NCT05100654 still lists

NCT05100654 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 207-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (286% higher).

The record links to 2 conditions, with Erectile Dysfunction appearing as the primary indexed condition, and to 4 interventions - of which Ciprofloxacin is the first listed.

NCT05100654 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05100654 about?

NCT05100654 is a clinical study titled "Collaborative Urological Prosthetics Investigation Directive Research Group". The purpose of this study is to determine if an additional 6 days of oral antibiotics decreases the risk of penile prosthesis infection after implantation.

What is the current status of trial NCT05100654?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 800 participants. The study started on 2022-04-22. Estimated completion is 2028-01-01.

What conditions does trial NCT05100654 study?

This clinical trial studies the following conditions: Erectile Dysfunction, Penile Prosthesis Infection.

What interventions are being tested in trial NCT05100654?

The interventions under investigation include: Ciprofloxacin (DRUG), Doxycycline (DRUG), Augmentin (DRUG), Bactrim (DRUG).

Who is sponsoring clinical trial NCT05100654?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05100654 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Erectile Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05100654's enrollment target sits among peer trials

800 2nd of 33 the highest of 33 other Erectile Dysfunction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05100654, the US trial registry maintained by the National Library of Medicine. NCT05100654 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.